Building the Next Generation of AI-Designed and Tested Biological Medicines (formerly Cytonus Therapeutics).
San Diego, CA
Joined January 2019
- Tweets357
- Following819
- Followers225
- Likes323
Today at AMM ASCENT 2026 in Coronado, Calif., Axiom Biosciences CEO Remo Moomiaie-Qajar, M.D., takes the stage for a fireside chat on the investment landscape shaping the mRNA sector from 2-2:40 p.m. PT.
Follow along for highlights. #mRNA
Later this week at #AMMASCENT2026 in Coronado, Calif., Axiom Biosciences CEO Remo Moomiaie-Qajar, M.D., will join a fireside chat on the funding climate for mRNA, covering market dynamics, acquisitions and trends.
📅 Oct. 29 | 2–2:40 p.m. PT
Attending? Let's connect. #mRNA
CEO Remo Moomiaie-Qajar, M.D., joins Erin Harris on Episode 140 of Cell & Gene: The Podcast to discuss delivery-first platforms across stem cells, nanoparticles and mRNA, and putting new FDA guidance into practice 🎧
bit.ly/4zE2Crq | YouTube: youtube.com/watch?v=CxOsRnAU…
What's ahead for mRNA financing and investment?
Axiom Biosciences CEO Remo Moomiaie-Qajar, M.D., joins industry leaders at #AMMASCENT2026 on Oct. 29 for a fireside chat on funding trends, acquisitions and valuations.
Full agenda: bit.ly/3WdrzM1
IVH and HIE are different forms of severe neonatal brain injury, but both can have lifelong consequences.
Axiom's lead regenerative medicine program is being developed for newborns affected by these conditions, with planned Phase 2 development following positive Phase 1 results.
At Axiom Biosciences, we are developing advanced therapeutics designed to restore damaged tissue and address diseases where conventional approaches have fallen short.
Our work spans regenerative medicine and targeted biologics.
Learn more: bit.ly/4xcRSyC
Axiom Biosciences is taking a different route to the public markets. CEO Remo Moomiaie-Qajar, M.D., shares insight with @SDbusiness on the company's plans to pursue a Hong Kong IPO. bit.ly/4z2FF0S #HKEX
This week, CEO Remo Moomiaie-Qajar, M.D., was in Hong Kong and met with partners across the region's capital markets and biotech community and the media, building on our announced intention to pursue a primary listing on The Stock Exchange of Hong Kong.
@HKEXGroup #HKEX @KPMG
Axiom Biosciences’ partnership with GeneFab is featured in @ContractPharma, highlighting development and manufacturing support for Axiom’s clinical-stage therapeutic programs.
Read more: bit.ly/4AlcTtO
Axiom Biosciences has partnered with GeneFab, a cell and gene therapy CDMO, to support Axiom’s manufacturing and clinical development capabilities as the company prepares for upcoming activities across its lead therapeutic programs.
More: bit.ly/4yDTens
In a @BioSpace roundup of five destinations drawing biopharma investment beyond China, Axiom's planned #HKEX listing was featured. Hong Kong makes the list as the second largest biotech funding platform worldwide behind #Nasdaq, with $17.5B+ raised. bit.ly/4ylMGcW
Wharton's jelly is the gelatinous tissue inside the umbilical cord. For most of medical history, it was discarded at birth.
It turns out to be one of the richest available sources of mesenchymal stem cells, collected without an invasive procedure.
axiombio.co/
Our programs bring together stem cells, nanoparticles, mRNA and fusion proteins with AI-enabled drug design to develop highly targeted therapies.
These platforms form the foundation of our work across regenerative medicine and targeted biologics.
More: bit.ly/45PSBuz
For every minute the brain goes without blood flow, an estimated 1.9 million brain cells die.
That figure is why time is the defining variable in brain injury. CEO Remo Moomiaie-Qajar, M.D., breaks it down. Watch the clip: youtube.com/shorts/Yb2PrGhsi…
In our Phase 1 trial, our investigational therapy achieved a 0% mortality rate at 12 months, compared to the historical natural mortality rate of approximately 46% within the first year of life for infants with severe IVH.
ICYMI, dive in: bit.ly/4vtCEEI
Axiom Biosciences’ proposed Hong Kong IPO is part of a broader @BioSpace look at Hong Kong’s growing biotech ecosystem, including its connections to capital, clinical development and international companies.
Read more: bit.ly/4gqICkj
Stem cells have been studied across 1,500-plus clinical trials, & their central challenge has stayed the same. They are hard to control. Our approach preconditions the cells first, simulating the environment they will face in the body before treatment, to take the guesswork out.
Axiom Biosciences' proposed Hong Kong IPO is featured in a new @GENbio episode of Touching Base! with CEO Dr. Remo Moomiaie-Qajar, covering the company's listing strategy, clinical progress and vision for its next phase.
Listen to the interview: bit.ly/4cpoQUX
Axiom Biosciences CEO Dr. Remo Moomiaie-Qajar recently spoke with @GENbio about the company’s proposed Hong Kong IPO, global biotechnology strategy and the clinical progress shaping Axiom’s next stage of growth.
Read the interview: bit.ly/4pQoyw7 #HKEX
CEO Remo Moomiaie-Qajar, M.D., joined The Biotech Voyager for a full conversation on Axiom's investigational stem cell therapy, the science behind it, and preliminary Phase 1 findings in this patient population.
youtube.com/watch?v=OQxKc4IU…
